Lv0
0 积分 2024-01-16 加入
A phase 1 study of HRS-1167 (M9466), a highly selective PARP1 inhibitor, in patients (pts) with advanced solid tumors
1天前
求助中
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
15天前
已完结
EV260/#767 Phase I study of HCW9218, a bifunctional TGF- β antagonist/IL-15 protein complex, in patients with advanced, recurrent solid tumors
28天前
已关闭
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Molecular classification of hormone receptor-positive HER2-negative breast cancer
1个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
2个月前
已完结
Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors
2个月前
已完结
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial
2个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2个月前
已完结
皖公网安备34019202002308
